Cytisine inhibits the anticonvulsant activity of phenytoin and lamotrigine in mice

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 195-200

  Tutka, Piotr ^a,b   Mróz, Tomasz ^b   Bednarski, Jerzy ^b   Styk, Andrzej ^b   Ognik, Jaromir ^b   Mosiewicz, Jerzy ^b   Łuszczki, Jarogniew ^b,c  

^a UNIVERSITY OF RZESZÓW   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Cytisine; Epilepsy; Lamotrigine; Maximal electroshock; Nicotinic receptors; Phenytoin; Smoking cessation

Indexed keywords

CARBAMAZEPINE; CYTISINE; LAMITRIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTRIC SHOCK; EXPERIMENTAL MODEL; MALE; MOUSE; NONHUMAN; PROTECTION; SINGLE DRUG DOSE; SMOKING CESSATION; TONIC CLONIC SEIZURE;

EID: 84875802411     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)70978-2     Document Type: Article

References (21)

1. Caulfield MP, Higgins GA: Mediation of nicotineinduced convulsions by central nicotinic receptors of the 'C6' type. Neuropharmacology, 1983, 22, 347-351.
2. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB et al.: Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 2005, 48, 3474-3477.
3. Damaj MI, Glassco W, Dukat M, Martin BR: Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther, 1999, 291, 1284-1291.
4. Etter JF: Cytisine for smoking cessation, a literature review and a meta-analysis. Arch Intern Med, 2006, 166, 1553-1559.
5. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
6. Łuszczki JJ, Czuczwar SJ: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep, 2005, 57, 782-786.
7. Łuszczki JJ, Jaskólska A, Dworzański W, Żółkowska D: 7-Nitroindazole, but not NG-nitro-L-arginine, enhances the anticonvulsant activity of pregabalin in the mouse maximal electroshock-induced seizure model. Pharmacol Rep, 2011, 63, 169-175.
8. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science, 1995, 269, 1692-1696.
9. Papke RL, Heinemann SF: Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol Pharmacol, 1994, 45, 142-149.
10. Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, Tseng E et al.: Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol, 160, 334-345.
11. Sood N, Hota D, Sahai AK, Chakrabarti A: Nicotine reversal of anticonvulsant action of topiramate in kainic acid-induced seizure model in mice. Nicotine Tob Res, 2011, 13, 1084-1091.
12. Stitzel JA, Lu Y, Jimenez M, Tritto T, Collins AC: Genetic and pharmacological strategies identify a behavioral function of neuronal nicotinic receptors. Behav Brain Res, 2000, 113, 57-64.
13. Stoyanov S, Yanachkova M: Tabex - therapeutic efficacy and tolerance (in Bulgarian). Savr Med, 1972, 23, 30-33.
14. Thompson-Evans TP, Glover M, Walker N: Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: a qualitative study with Maori. Nicotine Tob Res, 2011, 13, 353-360.
15. Tutka P: Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin Investig Drugs, 2008, 17, 1473-1485.
16. Tutka P, Zatoński W: Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep, 2006, 58, 777-798.
17. Vinnikov D, Brimkulov N, Burjubaeva A: A doubleblind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat, 2008, 3, 57-62.
18. West R, Zatoński W, Cedzyńska M, Lewandowska D, Pazik J, Aveyard P, Stapleton J: Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med, 2011, 365, 1193-1200.
19. Wood HC: Preliminary notes on a new medicinal plant and its alkaloid. Phyladelphia Medical Times, 1877, 7, 510.
20. Xi ZX: Preclinical pharmacology, efficacy and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug Health Patient Saf, 2010, 2, 39-48.
21. Zatoński W, Cedzyńska M, Tutka P, West R: An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control, 2006, 15, 481-484.